Drug Type Small molecule drug |
Synonyms Dextran sulfate sodium (JAN), IBsolvMIR, TM-400 + [3] |
Mechanism Coagulation factor inhibitors, Complement system proteins inhibitors, Stem cells modulators |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Start Date08 Feb 2021 |
Sponsor / Collaborator |
Start Date29 Mar 2019 |
Sponsor / Collaborator |
Start Date15 Aug 2018 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02047 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatitis, Chronic | Phase 2 | SE | 15 Jul 2022 | |
Diabetes Mellitus, Type 1 | Phase 2 | NL | 08 Feb 2021 | |
Diabetes Mellitus, Type 1 | Phase 2 | NO | 08 Feb 2021 | |
Diabetes Mellitus, Type 1 | Phase 2 | SE | 08 Feb 2021 | |
Amyotrophic Lateral Sclerosis | Phase 2 | GB | 16 Jul 2018 | |
Rejection of pancreas transplant | Phase 2 | SE | - | 04 Mar 2009 |
Hematologic Neoplasms | Phase 1 | - | - | |
Stem cell mobilisation | Phase 1 | SE | - | |
Brain Injuries, Traumatic | Preclinical | SE | - | |
Glaucoma | Preclinical | SE | - |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | - | Dextran Sodium Sulfate | httedhmmen(oadxdfsqjm) = uegtiduhrj cpjkljpyaw (nxykbuhsfr ) | Positive | 01 Apr 2010 |